Liquidia Corporation announced a global settlement with United Therapeutics, resolving all pending patent litigation. This settlement requires Liquidia to pay United Therapeutics a total of $380.7 million and remove the PH-ILD indication from its YUTREPIA label, significantly impacting its product strategy and financial outlook.
Liquidia Corporation has reached a global settlement with United Therapeutics, ending all ongoing patent litigation. This resolution follows a court ruling that found Liquidia infringed on UTHR's patents related to inhaled treprostinil treatment for PH-ILD, leading Liquidia to agree to remove this indication from its YUTREPIA label. The financial terms involve Liquidia paying UTHR a total of $380.7 million in installments. For LQDA, this removes a significant legal overhang, which is why the stock jumped in after-hours trading despite the substantial payout. For UTHR, it represents a significant financial gain and protection of its patent rights. Short-term, LQDA faces substantial cash outflows, but the clarity on YUTREPIA's market scope (focusing on PAH) and the end of litigation uncertainty are positive. The key opportunity for traders is the potential for LQDA to re-rate now that the legal cloud has lifted, while UTHR benefits from the cash infusion and patent validation.